JAMDA
June 22, 2018
Showing 931 - 940 of 9066 results
JAMDA
September 25, 2023
Antipsychotic Drug Reduction through the Implementation of a Neurologically Oriented, Interdisciplinary Psycho-Diagnostic and Antipsychotic Stewardship Program
Antipsychotic utilization in skilled nursing facilities (SNFs) is a major focus of regulatory compliance and a key theme in resident care. This created opportunities for innovations in clinical care of behavioral and psychological symptoms of dementia (BPSD). In a shared initiative with one of our SNF oper...
JAMDA
February 27, 2016
Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients
To assess the long-term mortality risk associated with antipsychotic drug (AP) use in nursing homes.
JAMDA
August 4, 2020
Antipsychotic Drugs and Hip Fracture: Associations Before and After the Initiation of Treatment
To study the association between antipsychotic drug treatment and hip fracture, before and after the initiation of treatment.
JAMDA
February 25, 2020
Antipsychotic Drugs, Fracture Risk, and Frailty in Older Patients
Caring for the Ages
April 4, 2023
Antipsychotic Prescribing Varies Widely Among States
Other Event
Jun 23, 2026 11:30 am - Jun 23, 2026 1:30 pm
Antipsychotic Stewardship in SNFs: Project PAUSE, the Updated Long-Stay Metric, Boxed Warnings, and the Consultant Pharmacist’s Essential Role in Regulatory Compliance and Resident-Centered Care
This APEX webinar delivers practical, up-to-date guidance on appropriate antipsychotic management, spotlighting the consultant pharmacist’s leadership role in balancing safety, regulatory requirements, and resident quality of life. Join us for an in-depth exploration of Project PAUSE (Psychoactive Appropriate Use for Safety and Effectiveness), the national coalition — with ASCP as a key convener — that has driven national advocacy for evidence-based antipsychotic use in nursing homes.
Read More
JAMDA
February 26, 2019
Antipsychotic Treatment Associated With Increased Mortality Risk in Patients With Dementia. A Registry-Based Observational Cohort Study
To assess all-cause mortality patients with dementia treated with typical and atypical antipsychotic drugs (APDs).
JAMDA
October 28, 2021
Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer’s Disease
Antipsychotic use for neuropsychiatric symptoms in Alzheimer’s disease (AD) is common despite the increased risk of cardiovascular events and mortality. There is limited and inconsistent evidence on the possible risk of stroke. We assessed whether antipsychotic initiation increases the risk of stroke in pe...
JAMDA
February 6, 2025
Antipsychotic Use in Older Adults with Dementia: Community and Nursing Facility Trends in Texas, 2015-2020
To assess recent trends in antipsychotic use among older adults with Alzheimer's disease and related dementias (ADRDs) according to their residential status and determine the factors associated with the use of antipsychotics.
